Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. März 2017 16:18 ET | Quelle: Otonomy, Inc.

Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

Topline data for OTO-104 Phase 3 trials in Ménière’s disease expected in 2H2017 Implemented changes to commercial organization to improve OTIPRIO® sales performance Company to host conference call...
28. Februar 2017 16:05 ET | Quelle: Otonomy, Inc.

Otonomy to Present at Cowen and Company Health Care Conference

SAN DIEGO, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
24. Februar 2017 07:30 ET | Quelle: Otonomy, Inc.

Otonomy to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
19. Januar 2017 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss

SAN DIEGO, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
09. Januar 2017 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Provides Corporate and Product Pipeline Update

SAN DIEGO, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
05. Januar 2017 07:00 ET | Quelle: Otonomy, Inc.

Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa

SAN DIEGO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
03. Januar 2017 07:30 ET | Quelle: Otonomy, Inc.

Otonomy to Present at the J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
30. November 2016 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Appoints Kathie M. Bishop, Ph.D., as Chief Scientific Officer

SAN DIEGO, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
22. November 2016 16:05 ET | Quelle: Otonomy, Inc.

Otonomy to Present at Piper Jaffray Healthcare Conference

SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
03. November 2016 16:13 ET | Quelle: Otonomy, Inc.

Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...

Vorherige Seite